TY - JOUR
T1 - An in vivo platform for translational drug development in pancreatic cancer
AU - Rubio-Viqueira, Belen
AU - Jimeno, Antonio
AU - Cusatis, George
AU - Zhang, Xianfeng
AU - Iacobuzio-Donahue, Christine
AU - Karikari, Collins
AU - Shi, Chanjusn
AU - Danenberg, Kathleen
AU - Danenberg, Peter V.
AU - Kuramochi, Hidekazu
AU - Tanaka, Koji
AU - Singh, Sharat
AU - Salimi-Moosavi, Hossein
AU - Bouraoud, Nadia
AU - Amador, Maria L.
AU - Altiok, Soner
AU - Kulesza, Piotr
AU - Yeo, Charles
AU - Messersmith, Wells
AU - Eshleman, James
AU - Hruban, Ralph H.
AU - Maitra, Anirban
AU - Hidalgo, Manuel
PY - 2006/8/1
Y1 - 2006/8/1
N2 - Effective development of targeted anticancer agents includes the definition of the optimal biological dose and biomarkers of drug activity. Currently available preclinical models are not optimal to this end. We aimed at generating a model for translational drug development using pancreatic cancer as a prototype. Resected pancreatic cancers from 14 patients were xenografted and expanded in successive groups of nude mice to develop cohorts of tumor-bearing mice suitable for drug therapy in simulated early clinical trials. The xenografted tumors maintain their fundamental genotypic features despite serial passages and recapitulate the genetic heterogeneity of pancreatic cancer. The in vivo platform is useful for integrating drug screening with biomarker discovery. Passages of tumors in successive cohorts of mice do not change their susceptibility to anticancer agents and represent a perpetual live bank, facilitating the application of new technologies that will result in the creation of an integrated stable database of tumor-drug response data and biomarkers.
AB - Effective development of targeted anticancer agents includes the definition of the optimal biological dose and biomarkers of drug activity. Currently available preclinical models are not optimal to this end. We aimed at generating a model for translational drug development using pancreatic cancer as a prototype. Resected pancreatic cancers from 14 patients were xenografted and expanded in successive groups of nude mice to develop cohorts of tumor-bearing mice suitable for drug therapy in simulated early clinical trials. The xenografted tumors maintain their fundamental genotypic features despite serial passages and recapitulate the genetic heterogeneity of pancreatic cancer. The in vivo platform is useful for integrating drug screening with biomarker discovery. Passages of tumors in successive cohorts of mice do not change their susceptibility to anticancer agents and represent a perpetual live bank, facilitating the application of new technologies that will result in the creation of an integrated stable database of tumor-drug response data and biomarkers.
UR - http://www.scopus.com/inward/record.url?scp=33748088524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748088524&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-06-0113
DO - 10.1158/1078-0432.CCR-06-0113
M3 - Article
C2 - 16899615
AN - SCOPUS:33748088524
SN - 1078-0432
VL - 12
SP - 4652
EP - 4661
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 15
ER -